Drug Discovery World
FEBRUARY 19, 2024
Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).
Drug Discovery World
AUGUST 30, 2024
As we gear up for Phase I clinical trials in the first half of 2024, we’re aiming to evaluate the safety of our innovative CD5 knockout strategy enabled by our novel cell therapy and manufacturing platform. Beyond VIPER-101, we’re developing subsequent programmes for autoimmune disease and solid tumours.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 22, 2024
She discusses with DDW’s Megan Thomas the company’s lead programme; a gene therapy called ER-100. This is the sweet spot for developing therapeutics where you can restore cells to a more youthful state, while maintaining cell identity.” Sharon Rosenzweig-Lipson , PhD, is Chief Scientific Officer of Life Biosciences.
Drug Discovery World
AUGUST 28, 2024
Under the collaboration, the companies will analyse somatic mutations that occur in diseased patient tissue to inform the discovery and development of therapies for cardiovascular and renal diseases. The collaboration was the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer.
Drug Discovery World
FEBRUARY 13, 2023
Hosted by DDW and supported by Benchling and BPS Bioscience, Cell and gene therapy: sustaining growth and maximising opportunities will be free to attend on February 17 at 8am PST / 11am EST / 4pm GMT / 5pm CET. Cell and gene therapies (CGT) are transforming the way diseases are treated.
Drug Discovery World
AUGUST 7, 2024
.” Shinobi’s immune evasive iPS-T cell technology, built upon a decade of research by co-founders Shin Kaneko at Kyoto University and Tobias Deuse at University of California, San Francisco, enables a new class of off-the-shelf cell therapies.
Drug Discovery World
APRIL 14, 2023
Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated, safe and developable bi-specific therapeutic ADC candidates to clinical development. He says it is no secret that the costs of antibody drug development are steadily increasing to ‘eye-watering heights’ per approved drug 1.
Expert insights. Personalized for you.
148 
Let's personalize your content